

VALUE FOCUS

# Medtech & Device Industry

## Fourth Quarter 2023

This quarterly update includes a broad outlook that divides the healthcare industry into four sectors: Biotechnology & Life Sciences, Medical Devices, Healthcare Technology, and Large, Diversified Healthcare Companies.

We include a review of market performance, valuation multiple trends, operating metrics, and other market data. This issue also includes a review of M&A and IPO activity during the third quarter of 2023.



# Medtech & Device Industry Services

Mercer Capital provides valuation services to start ups, larger public and private companies, and private equity and venture capital funds.

Mercer Capital's expertise in the medtech and device industry spans the following segments:

- Biotechnology and life sciences
- Medical devices
- Healthcare technology
- Large, diversified

Our services include:

- Purchase price allocations
- Impairment testing
- Portfolio valuation for LP reporting
- Transaction and valuation advisory
- Equity compensation valuation for tax compliance

Contact a Mercer Capital professional to discuss your needs in confidence.

## Contact Us



**Sujan Rajbhandary, CFA, ABV**

901.322.9749

[sujanr@mercercapital.com](mailto:sujanr@mercercapital.com)



**J. David Smith, ASA, CFA**

713.239.1005

[smithd@mercercapital.com](mailto:smithd@mercercapital.com)



**Travis W. Harms, CFA, CPA/ABV**

901.322.9760

[harmst@mercercapital.com](mailto:harmst@mercercapital.com)



**Daniel P. McLeod, CFA**

901.322.9716

[mcleodd@mercercapital.com](mailto:mcleodd@mercercapital.com)



**J. Davis Rolfe, Jr., CPA**

901.322.9712

[rolfed@mercercapital.com](mailto:rolfed@mercercapital.com)

Follow us on  **@mercercapital**

Copyright © 2023 Mercer Capital Management, Inc. All rights reserved. It is illegal under Federal law to reproduce this publication or any portion of its contents without the publisher's permission. Media quotations with source attribution are encouraged. Reporters requesting additional information or editorial comment should contact Barbara Walters Price at 901.685.2120. Mercer Capital's Industry Focus is published quarterly and does not constitute legal or financial consulting advice. It is offered as an information service to our clients and friends. Those interested in specific guidance for legal or accounting matters should seek competent professional advice. Inquiries to discuss specific valuation matters are welcomed. To add your name to our mailing list to receive this complimentary publication, visit our web site at [www.mercercapital.com](http://www.mercercapital.com).

## In This Issue

|                                 |    |
|---------------------------------|----|
| Stock Market Performance        | 2  |
| Revenue Multiples               | 5  |
| EBITDA Multiples                | 6  |
| Select Operating Metrics        | 7  |
| Public Medical Device Companies | 8  |
| Mergers & Acquisitions          | 12 |
| Initial Public Offerings        | 15 |

Learn More about Mercer Capital &  
our Medtech & Device Services at

[www.mercercapital.com](http://www.mercercapital.com)

## Stock Market Performance


The S&P 500 declined 3.6% during the third quarter of 2023 after increasing 8.3% in the prior quarter. Among the medtech industry sub-sectors tracked by Mercer Capital, the medical devices group underperformed the broader index over 3Q23. The healthcare technology group outperformed all other groups. The large, diversified group and the biotechnology & life sciences groups posted negative returns over the quarter, albeit better than the broader index.

- A market-capitalization weighted index of companies included in our biotechnology and life sciences sub-sector declined 2.2% over the quarter ended September 2023. The top performer of the group was Regeneron Pharmaceuticals, Inc., which posted a 14.5% return. REGN is a Tarrytown, New York-based company that develops, manufactures, and commercializes medicines for treating a variety of diseases including, among others, macular degeneration, atopic dermatitis, cutaneous squamous cell carcinoma, atherosclerotic cardiovascular disease, and rheumatoid arthritis.
- The medical device index fell 14.2% in 3Q23. Companies across the group performed poorly. The best performer was Boston Scientific Corporation with a quarterly return of negative 2.4%. BSX is a Massachusetts-based company that develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide.
- The healthcare technology index increased 0.5% over the quarter. Veradigm, Inc., up 46.3%, outperformed all other constituents of the group. MDRX is a Chicago-based healthcare technology company that provides information technology solutions and services to healthcare organizations in the US, Canada, and internationally.
- The large, diversified companies as a group returned negative 1.0% over the quarter. The top performer was Amgen, Inc. up 22.0% during the period. AMGN develops, manufactures, and delivers human therapeutics worldwide, focusing on inflammation, oncology, bone health, cardiovascular disease, nephrology, and neuroscience areas.

# Stock Market Performance

(continued)

3Q 2023 Stock Price Performance




Individual sub-sector performance represented by market capitalization weighted indices for each group.  
Data Source: Bloomberg LP; Mercer Capital Analysis


# Stock Market Performance

(continued)

YTD Stock Price Performance



LTM Stock Price Performance



Individual sub-sector performance represented by market capitalization weighted indices for each group.  
Source: Bloomberg LP; Mercer Capital Analysis


# Revenue Multiples

■ 75% Quartile ■ Median ■ 25% Quartile

Median Revenue multiples from each MCM group. Data source: Bloomberg


## Biotechnology & Life Sciences

EV / Trailing LTM Revenue




## Medical Devices

EV / Trailing LTM Revenue




## Healthcare Technology

EV / Trailing LTM Revenue



## Large, Diversified

EV / Trailing LTM Revenue




# EBITDA Multiples

■ 75% Quartile ■ Median ■ 25% Quartile

Median EBITDA multiples from each MCM group. Data source: Bloomberg


## Biotechnology & Life Sciences

EV / Trailing LTM EBITDA




## Medical Devices

EV / Trailing LTM EBITDA




## Healthcare Technology

EV / Trailing LTM EBITDA



## Large, Diversified

EV / Trailing LTM EBITDA



# Select Operating Metrics

| Sector                        | TTM Gross Margin |              | TTM Operating Margin |              | TTM R&D / Revenue |             | TTM EBITDA Margin |              |
|-------------------------------|------------------|--------------|----------------------|--------------|-------------------|-------------|-------------------|--------------|
|                               | 3Q 2023          | 2Q 2023      | 3Q 2023              | 2Q 2023      | 3Q 2023           | 2Q 2023     | 3Q 2023           | 2Q 2023      |
| Biotechnology & Life Sciences | 61.4%            | 62.2%        | 19.4%                | 24.0%        | 21.4%             | 20.3%       | 27.8%             | 31.8%        |
| Medical Devices               | 63.3%            | 62.8%        | 17.3%                | 17.3%        | 6.9%              | 7.1%        | 29.2%             | 29.4%        |
| Healthcare Technology         | 58.5%            | 58.9%        | 5.4%                 | 4.5%         | 13.1%             | 13.5%       | 19.9%             | 18.9%        |
| Large, Diversified            | 57.0%            | 57.4%        | 18.2%                | 19.0%        | 8.8%              | 8.7%        | 31.5%             | 32.4%        |
| <b>Overall Median</b>         | <b>59.6%</b>     | <b>59.7%</b> | <b>16.8%</b>         | <b>17.1%</b> | <b>8.3%</b>       | <b>8.1%</b> | <b>28.9%</b>      | <b>29.5%</b> |

| Sector                        | Revenue Growth |             | L-T FWD Op. Earn. Growth |             | Debt / EV    |              | Debt / EBITDA |            |
|-------------------------------|----------------|-------------|--------------------------|-------------|--------------|--------------|---------------|------------|
|                               | Q / Q          | Y / Y       | 3Q 2023                  | 2Q 2023     | 3Q 2023      | 2Q 2023      | 3Q 2023       | 2Q 2023    |
| Biotechnology & Life Sciences | 0.2%           | 0.6%        | 4.2%                     | 9.7%        | 11.7%        | 8.5%         | 2.4           | 1.8        |
| Medical Devices               | 1.9%           | 4.8%        | 8.0%                     | 10.6%       | 11.5%        | 10.5%        | 2.2           | 1.8        |
| Healthcare Technology         | 2.0%           | 11.0%       | 8.8%                     | 9.4%        | 17.0%        | 12.9%        | 2.1           | 0.4        |
| Large, Diversified            | -0.2%          | -3.2%       | 3.8%                     | 5.9%        | 17.1%        | 20.3%        | 2.5           | 2.8        |
| <b>Overall Median</b>         | <b>1.1%</b>    | <b>0.9%</b> | <b>7.1%</b>              | <b>9.4%</b> | <b>14.0%</b> | <b>10.7%</b> | <b>2.3</b>    | <b>2.0</b> |

Median measures for each group. | Data Source: Bloomberg

## Public Medical Device Companies

|                                          |      | Price   |         |         | Δ Stock Price |              | EV       | TTM Rev | TTM EBITDA | FWD EBITDA |         | EV / Rev.    | EV / EBITDA  | EV / FWD EBITDA |              |
|------------------------------------------|------|---------|---------|---------|---------------|--------------|----------|---------|------------|------------|---------|--------------|--------------|-----------------|--------------|
|                                          |      | 3Q 2023 | 2Q 2023 | 3Q 2022 | Quarterly     | Annual       | 3Q 2023  | 3Q 2023 | 3Q 2023    | FY 2024    | FY 2025 | 3Q 2023      | 3Q 2023      | 2024            | 2025         |
| <b>Biotechnology &amp; Life Sciences</b> |      |         |         |         |               |              |          |         |            |            |         |              |              |                 |              |
| Biogen Inc                               | BIIB | \$257   | \$285   | \$267   | -9.8%         | -3.7%        | \$42,642 | \$9,993 | \$2,697    | \$2,941    | \$3,384 | 4.27x        | 15.8x        | 14.5x           | 12.6x        |
| Bio-Rad Laboratories Inc                 | BIO  | 358     | 379     | 417     | -5.5%         | -14.1%       | 10,069   | 2,720   | 622        | 516        | 546     | 3.70         | 16.2         | 19.5            | 18.4         |
| BioMarin Pharmaceutical Inc              | BMRN | 88      | 87      | 85      | 2.1%          | 4.4%         | 16,124   | 2,311   | 234        | 350        | 633     | 6.98         | 68.9         | 46.1            | 25.5         |
| Sartorius Stedim Biotech                 | DIM  | 239     | 250     | 309     | -4.3%         | -22.6%       | 25,925   | 3,150   | 898        | 781        | 953     | 8.23         | 28.9         | 33.2            | 27.2         |
| Eurofins Scientific SE                   | ERF  | 57      | 62      | 59      | -9.3%         | -3.8%        | 14,838   | 6,816   | 1,301      | 1,334      | 1,493   | 2.18         | 11.4         | 11.1            | 9.9          |
| Gilead Sciences Inc                      | GILD | 75      | 76      | 59      | -1.8%         | 26.1%        | 110,404  | 27,391  | 11,923     | 12,009     | 12,763  | 4.03         | 9.3          | 9.2             | 8.7          |
| Illumina Inc                             | ILMN | 137     | 187     | 191     | -26.8%        | -28.0%       | 22,944   | 4,465   | 418        | 442        | 548     | 5.14         | 54.9         | 52.0            | 41.9         |
| Incyte Corp                              | INCY | 58      | 62      | 67      | -7.2%         | -13.3%       | 9,430    | 3,609   | 638        | 815        | 1,167   | 2.61         | 14.8         | 11.6            | 8.1          |
| IQVIA Holdings Inc                       | IQV  | 197     | 225     | 181     | -12.5%        | 8.6%         | 48,541   | 14,855  | 3,329      | 3,567      | 3,799   | 3.27         | 14.6         | 13.6            | 12.8         |
| Lonza Group AG                           | LONN | 465     | 596     | 491     | -21.9%        | -5.3%        | 35,510   | 6,736   | 2,447      | 1,883      | 1,966   | 5.27         | 14.5         | 18.9            | 18.1         |
| Mettler-Toledo International Inc         | MTD  | 1,108   | 1,312   | 1,084   | -15.5%        | 2.2%         | 26,267   | 3,911   | 1,275      | 1,235      | 1,224   | 6.72         | 20.6         | 21.3            | 21.5         |
| Regeneron Pharmaceuticals Inc            | REGN | 823     | 719     | 689     | 14.5%         | 19.5%        | 76,631   | 13,097  | 5,021      | 5,291      | 5,320   | 5.85         | 15.3         | 14.5            | 14.4         |
| Vertex Pharmaceuticals Inc               | VRTX | 348     | 352     | 290     | -1.2%         | 20.1%        | 78,461   | 9,654   | 4,605      | 4,604      | 5,100   | 8.13         | 17.0         | 17.0            | 15.4         |
| Waters Corp                              | WAT  | 274     | 267     | 270     | 2.9%          | 1.7%         | 18,446   | 2,995   | 1,035      | 1,051      | 1,083   | 6.16         | 17.8         | 17.6            | 17.0         |
| <b>Group Median</b>                      |      |         |         |         | <b>-6.3%</b>  | <b>-1.0%</b> |          |         |            |            |         | <b>5.21x</b> | <b>16.0x</b> | <b>17.3x</b>    | <b>16.2x</b> |

(\$Millions, except per share figures)

Data Source: Bloomberg

## Public Medical Device Companies (continued)

|                            |       | Price   |         |         | Δ Stock Price |             | EV       | TTM Rev | TTM EBITDA | FWD EBITDA |           | EV / Rev.    | EV / EBITDA  | EV / FWD EBITDA |              |
|----------------------------|-------|---------|---------|---------|---------------|-------------|----------|---------|------------|------------|-----------|--------------|--------------|-----------------|--------------|
|                            |       | 3Q 2023 | 2Q 2023 | 3Q 2022 | Quarterly     | Annual      | 3Q 2023  | 3Q 2023 | 3Q 2023    | FY 2024    | FY 2025   | 3Q 2023      | 3Q 2023      | 2024            | 2025         |
| <b>Medical Devices</b>     |       |         |         |         |               |             |          |         |            |            |           |              |              |                 |              |
| Terumo Corp                | TRUMF | \$27    | \$31    | \$28    | -15.6%        | -4.7%       | \$20,280 | \$6,131 | \$1,434    | \$207,230  | \$229,642 | 3.31x        | 14.1x        | 0.1x            | 0.1x         |
| Sysmex Corp                | SSMX  | 48      | 68      | 53      | -29.3%        | -10.1%      | 9,742    | 3,089   | 784        | 115,685    | 126,886   | 3.15         | 12.4         | 0.1             | 0.1          |
| Olympus Corp               | OCPNY | 13      | 16      | 19      | -17.2%        | -31.8%      | 17,641   | 6,445   | 1,946      | 186,827    | 249,694   | 2.74         | 9.1          | 0.1             | 0.1          |
| Align Technology Inc       | ALGN  | 305     | 354     | 207     | -13.7%        | 47.4%       | 22,192   | 3,807   | 738        | 865        | 926       | 5.83         | 30.1         | 25.7            | 24.0         |
| Baxter International Inc   | BAX   | 38      | 45      | 52      | -16.6%        | -28.1%      | 30,254   | 14,951  | 2,837      | 2,936      | 3,233     | 2.02         | 10.7         | 10.3            | 9.4          |
| Boston Scientific Corp     | BSX   | 53      | 54      | 39      | -2.4%         | 36.3%       | 85,576   | 13,757  | 3,971      | 4,052      | 4,574     | 6.22         | 21.6         | 21.1            | 18.7         |
| Coloplast A/S              | COLOB | 106     | 125     | 100     | -15.2%        | 6.2%        | 25,646   | 3,425   | 1,126      | 8,941      | 9,924     | 7.49         | 22.8         | 2.9             | 2.6          |
| Edwards Lifesciences Corp  | EW    | 69      | 94      | 83      | -26.6%        | -16.2%      | 40,941   | 5,819   | 1,915      | 1,896      | 2,128     | 7.04         | 21.4         | 21.6            | 19.2         |
| Hologic Inc                | HOLX  | 69      | 81      | 65      | -14.3%        | 7.6%        | 16,977   | 4,038   | 1,290      | 1,342      | 1,422     | 4.20         | 13.2         | 12.7            | 11.9         |
| IDEXX Laboratories Inc     | IDXX  | 437     | 502     | 326     | -12.9%        | 34.2%       | 37,034   | 3,588   | 1,205      | 1,217      | 1,317     | 10.32        | 30.7         | 30.4            | 28.1         |
| Intuitive Surgical Inc     | ISRG  | 292     | 342     | 187     | -14.5%        | 55.9%       | 102,302  | nm      | nm         | 2,749      | 3,194     | nm           | nm           | 37.2            | 32.0         |
| ResMed Inc                 | RMD   | 147     | 217     | 216     | -32.1%        | -31.7%      | 23,173   | 4,016   | 1,279      | 1,500      | 1,656     | 5.77         | 18.1         | 15.5            | 14.0         |
| Smith & Nephew PLC         | SN/   | 12      | 16      | 11      | -22.6%        | 8.6%        | 13,623   | 5,349   | 1,088      | 1,353      | 1,486     | 2.55         | 12.5         | 10.1            | 9.2          |
| Stryker Corp               | SYK   | 273     | 304     | 200     | -10.2%        | 36.4%       | 115,041  | 19,885  | 5,310      | 5,314      | 5,968     | 5.79         | 21.7         | 21.6            | 19.3         |
| Teleflex Inc               | TFX   | 196     | 242     | 200     | -18.7%        | -1.9%       | 10,695   | 2,959   | 864        | 855        | 921       | 3.61         | 12.4         | 12.5            | 11.6         |
| Zimmer Biomet Holdings Inc | ZBH   | 112     | 145     | 104     | -22.8%        | 8.2%        | 28,622   | 7,279   | 2,396      | 2,640      | 2,774     | 3.93         | 11.9         | 10.8            | 10.3         |
| <b>Group Median</b>        |       |         |         |         | <b>-16.1%</b> | <b>6.9%</b> |          |         |            |            |           | <b>4.20x</b> | <b>14.1x</b> | <b>12.6x</b>    | <b>11.8x</b> |

(\$Millions, except per share figures)

Data Source: Bloomberg

## Public Medical Device Companies (continued)

|                              |       | Price   |         |         | Δ Stock Price |               | EV       | TTM Rev | TTM EBITDA | FWD EBITDA |          | EV / Rev.    | EV / EBITDA  | EV / FWD EBITDA |              |
|------------------------------|-------|---------|---------|---------|---------------|---------------|----------|---------|------------|------------|----------|--------------|--------------|-----------------|--------------|
|                              |       | 3Q 2023 | 2Q 2023 | 3Q 2022 | Quarterly     | Annual        | 3Q 2023  | 3Q 2023 | 3Q 2023    | FY 2024    | FY 2025  | 3Q 2023      | 3Q 2023      | 2024            | 2025         |
| <b>Healthcare Technology</b> |       |         |         |         |               |               |          |         |            |            |          |              |              |                 |              |
| M3 Inc                       | MTHRY | \$18    | \$22    | \$28    | -15.6%        | -34.7%        | \$11,318 | \$1,749 | \$599      | \$83,632   | \$94,717 | 6.47x        | 18.9x        | 0.1x            | 0.1x         |
| Craneware PLC                | CRW   | 18      | 17      | 21      | 5.5%          | -13.3%        | 722      | 170     | 52         | 57         | 61       | 4.25         | 13.9         | 12.6            | 11.8         |
| Doximity Inc                 | DOCS  | 21      | 34      | 30      | -37.6%        | -29.8%        | 3,345    | 402     | 130        | 213        | 235      | 8.33         | 25.8         | 15.7            | 14.2         |
| Evolent Health Inc           | EVH   | 27      | 30      | 36      | -10.1%        | -24.2%        | 3,680    | 1,790   | 116        | 195        | 262      | 2.06         | 31.7         | 18.9            | 14.1         |
| HealthStream Inc             | HSTM  | 22      | 25      | 21      | -12.0%        | 1.8%          | 607      | 277     | 55         | 61         | 65       | 2.19         | 11.0         | 10.0            | 9.3          |
| Veradigm Inc                 | MDRX  | 13      | 13      | 15      | 4.3%          | -13.7%        | 1,436    | 152     | 40         | 174        | 177      | 9.45         | 35.7         | 8.3             | 8.1          |
| NextGen Healthcare Inc       | NXGN  | 24      | 16      | 18      | 46.3%         | 34.1%         | 1,625    | 626     | 60         | 128        | 150      | 2.60         | 27.0         | 12.7            | 10.8         |
| Omnicell Inc                 | OMCL  | 45      | 74      | 87      | -38.9%        | -48.2%        | 2,202    | 1,186   | 88         | 131        | 134      | 1.86         | 25.1         | 16.9            | 16.4         |
| Teladoc Health Inc           | TDOC  | 19      | 25      | 25      | -26.6%        | -26.7%        | 3,618    | 2,580   | 102        | 323        | 363      | 1.40         | 35.4         | 11.2            | 10.0         |
| Tabula Rasa HealthCare Inc   | TRHC  | 10      | 8       | 5       | 25.0%         | 114.8%        | 553      | 338     | (11)       | 22         | 33       | 1.63         | nm           | 25.1            | 16.9         |
| Veeva Systems Inc            | VEEV  | 203     | 198     | 165     | 2.9%          | 23.4%         | 29,718   | 2,077   | 512        | 850        | 1,046    | 14.31        | 58.0         | 35.0            | 28.4         |
| <b>Group Median</b>          |       |         |         |         | <b>-10.1%</b> | <b>-13.7%</b> |          |         |            |            |          | <b>2.60x</b> | <b>26.4x</b> | <b>12.7x</b>    | <b>11.8x</b> |

(\$Millions, except per share figures)

Data Source: Bloomberg

## Public Medical Device Companies (continued)

|                              |      | Price   |         |         | Δ Stock Price |             | EV       | TTM Rev | TTM EBITDA | FWD EBITDA |         | EV / Rev.    | EV / EBITDA  | EV / FWD EBITDA |              |
|------------------------------|------|---------|---------|---------|---------------|-------------|----------|---------|------------|------------|---------|--------------|--------------|-----------------|--------------|
|                              |      | 3Q 2023 | 2Q 2023 | 3Q 2022 | Quarterly     | Annual      | 3Q 2023  | 3Q 2023 | 3Q 2023    | FY 2024    | FY 2025 | 3Q 2023      | 3Q 2023      | 2024            | 2025         |
| <b>Large, Diversified</b>    |      |         |         |         |               |             |          |         |            |            |         |              |              |                 |              |
| Agilent Technologies Inc     | A    | \$112   | \$120   | \$120   | -7.0%         | -7.4%       | \$34,335 | \$6,994 | \$2,091    | \$2,027    | \$2,116 | 4.91x        | 16.4x        | 16.9x           | 16.2x        |
| AbbVie Inc                   | ABBV | 148     | 132     | 128     | 11.9%         | 15.6%       | 307,913  | 55,138  | 31,585     | 27,102     | 26,527  | 5.58         | 9.7          | 11.4            | 11.6         |
| Abbott Laboratories          | ABT  | 96      | 108     | 94      | -10.7%        | 2.0%        | 175,403  | 39,959  | 9,911      | 10,190     | 10,851  | 4.39         | 17.7         | 17.2            | 16.2         |
| Amgen Inc                    | AMGN | 269     | 220     | 218     | 22.0%         | 23.3%       | 169,487  | 26,833  | 14,029     | 15,163     | 17,376  | 6.32         | 12.1         | 11.2            | 9.8          |
| Becton Dickinson & Co        | BDX  | 259     | 263     | 220     | -1.7%         | 17.7%       | 90,853   | 19,046  | 6,610      | 5,552      | 5,345   | 4.77         | 13.7         | 16.4            | 17.0         |
| Danaher Corp                 | DHR  | 220     | 212     | 228     | 3.4%          | -3.6%       | 173,076  | 29,566  | 9,359      | 7,937      | 7,817   | 5.85         | 18.5         | 21.8            | 22.1         |
| Johnson & Johnson            | JNJ  | 156     | 164     | 159     | -5.2%         | -1.9%       | 411,071  | 83,703  | 38,402     | 31,905     | 32,997  | 4.91         | 10.7         | 12.9            | 12.5         |
| Medtronic PLC                | MDT  | 78      | 87      | 78      | -10.3%        | 0.4%        | 121,256  | 30,772  | 9,143      | 9,120      | 9,869   | 3.94         | 13.3         | 13.3            | 12.3         |
| Koninklijke Philips NV       | PHIA | 20      | 22      | 15      | -7.2%         | 33.8%       | 26,374   | 19,204  | 3,045      | 2,815      | 3,057   | 1.37         | 8.7          | 9.4             | 8.6          |
| Roche Holding AG             | ROG  | 274     | 306     | 317     | -10.4%        | -13.6%      | 239,171  | 65,699  | 25,109     | 22,803     | 24,345  | 3.64         | 9.5          | 10.5            | 9.8          |
| Siemens Healthineers AG      | SHL  | 51      | 57      | 42      | -10.3%        | 21.0%       | 73,626   | 22,626  | 4,078      | 4,670      | 5,357   | 3.25         | 18.1         | 15.8            | 13.7         |
| Thermo Fisher Scientific Inc | TMO  | 506     | 521     | 506     | -2.9%         | 0.1%        | 224,469  | 43,421  | 10,868     | 10,836     | 10,919  | 5.17         | 20.7         | 20.7            | 20.6         |
| <b>Group Median</b>          |      |         |         |         | <b>-6.1%</b>  | <b>1.2%</b> |          |         |            |            |         | <b>4.84x</b> | <b>13.5x</b> | <b>14.5x</b>    | <b>13.1x</b> |

(\$Millions, except per share figures)

Data Source: Bloomberg

## Mergers & Acquisitions

| Announced Transactions During 3Q 2023           |                                 |               |                   |            |            |       |        |                                  |
|-------------------------------------------------|---------------------------------|---------------|-------------------|------------|------------|-------|--------|----------------------------------|
| Acquirer                                        | Target                          | Announce Date | Transaction Value | Implied EV | Implied EV |       |        | Target Sector                    |
|                                                 |                                 |               |                   |            | Revenue    | EBIT  | EBITDA |                                  |
| Danaher Corporation                             | Abcam plc                       | 8/28/23       | 5,999             | 5,900      | 12.35      | 64.2  | 40.0   | Biotechnology                    |
| Thoma Bravo, L.P.; Thoma Bravo Discover Fund IV | NextGen Healthcare, Inc.        | 9/6/23        | 1,982             | 1,764      | 2.60       | 37.5  | 30.3   | Health Care Technology           |
| Eli Lilly and Company                           | Versanis Bio, Inc.              | 7/14/23       | 1,925             | 1,925      | nm         | nm    | nm     | Biotechnology                    |
| Revolution Medicines, Inc.                      | EQRx, Inc.                      | 8/1/23        | 1,587             | 325        | nm         | nm    | nm     | Biotechnology                    |
| TPG Capital, L.P.                               | Nextech Systems, LLC            | 7/19/23       | 1,400             | 1,400      | nm         | nm    | nm     | Health Care Technology           |
| Coloplast A/S                                   | Kerecis LLC                     | 7/7/23        | 1,300             | 1,300      | 17.48      | nm    | nm     | Biotechnology                    |
| Alfasigma S.p.A.                                | Intercept Pharmaceuticals, Inc. | 9/26/23       | 1,176             | 762        | 2.49       | nm    | nm     | Biotechnology                    |
| Novo Nordisk A/S                                | Inversago Pharma Inc.           | 8/10/23       | 1,075             | 1,075      | nm         | nm    | nm     | Biotechnology                    |
| Novartis AG                                     | DTx Pharma, Inc.                | 7/17/23       | 1,000             | 1,000      | nm         | nm    | nm     | Biotechnology                    |
| Thermo Fisher Scientific Inc.                   | CorEvitas, LLC                  | 7/6/23        | 914               | 910        | nm         | nm    | nm     | Health Care Technology           |
| Permira Advisers Ltd.                           | Ergomed plc                     | 9/4/23        | 912               | 888        | 4.84       | 34.3  | 27.1   | Life Sciences Tools and Services |
| Enovis Corporation                              | Limacorporate S.p.A.            | 9/25/23       | 867               | 842        | 2.95       | 129.8 | 23.7   | Health Care Equipment            |
| Boston Scientific Corporation                   | Relievant Medsystems, Inc.      | 9/19/23       | 850               | 850        | nm         | nm    | nm     | Health Care Equipment            |
| Exact Care Pharmacy, LLC                        | Tabula Rasa HealthCare, Inc.    | 8/7/23        | 658               | 595        | 1.76       | nm    | nm     | Health Care Technology           |
| Laborie Medical Technologies, Inc.              | Urotronic, Inc.                 | 9/6/23        | 546               | 569        | nm         | nm    | nm     | Health Care Equipment            |
| Novo Nordisk A/S                                | Embark Biotech ApS              | 8/30/23       | 515               | 515        | nm         | nm    | nm     | Biotechnology                    |
| Quince Therapeutics, Inc.                       | EryDel S.p.A.                   | 7/24/23       | 509               | 509        | nm         | nm    | nm     | Life Sciences Tools and Services |
| Elos Medtech AB (publ)                          | Klingel Holding GmbH            | 7/28/23       | 408               | na         | nm         | nm    | nm     | Health Care Equipment            |
| Korro Bio, Inc.                                 | Frequency Therapeutics, Inc.    | 7/14/23       | 326               |            | nm         | nm    | nm     | Biotechnology                    |
| DSM-Firmenich AG                                | Adare Pharmaceuticals SAS       | 7/3/23        | 300               | 300        | nm         | nm    | nm     | Biotechnology                    |
| Zoetis Inc.                                     | PetMedix Ltd                    | 9/15/23       | 285               | 262        | nm         | nm    | nm     | Life Sciences Tools and Services |
| ArchiMed SAS                                    | Instem plc                      | 8/30/23       | 245               | 234        | 2.99       | 29.3  | 19.9   | Health Care Technology           |

Transaction values over \$100 million; Presented in \$millions

Data Source: Capital IQ

Mergers & Acquisitions *(continued)*

| Announced Transactions During 3Q 2023 |                                                    |               |                   |            |            |      |        |                                  |
|---------------------------------------|----------------------------------------------------|---------------|-------------------|------------|------------|------|--------|----------------------------------|
| Acquirer                              | Target                                             | Announce Date | Transaction Value | Implied EV | Implied EV |      |        | Target Sector                    |
|                                       |                                                    |               |                   |            | Revenue    | EBIT | EBITDA |                                  |
| Regeneron Pharmaceuticals, Inc.       | Decibel Therapeutics, Inc.                         | 8/9/23        | 209               | 140        | nm         | nm   | nm     | Biotechnology                    |
| Neurogene Inc.                        | Neoleukin Therapeutics, Inc.                       | 7/18/23       | 180               | 180        | nm         | nm   | nm     | Biotechnology                    |
| Repligen Sweden AB                    | Metenova AB                                        | 9/26/23       | 173               | 173        | nm         | nm   | nm     | Life Sciences Tools and Services |
| CCL Industries Inc.                   | Faubel & Co. Nachf. GmbH                           | 7/31/23       | 141               | 141        | 2.82       | nm   | 6.1    | Life Sciences Tools and Services |
| Carmell Therapeutics Corporation      | Axolotl Biologix, Inc.                             | 7/27/23       | 140               | 140        | 2.80       | nm   | 28.0   | Biotechnology                    |
| Bruker Corporation                    | PhenomeX Inc. (nka:Bruker Cellular Analysis, Inc.) | 8/17/23       | 136               | 105        | 1.47       | nm   | nm     | Life Sciences Tools and Services |
| MediPacific, Inc.                     | Pardes Biosciences, Inc.                           | 7/17/23       | 131               | (22)       | nm         | nm   | nm     | Biotechnology                    |
| Mindray Medical Netherlands B.V.      | DiaSys Diagnostic Systems GmbH                     | 7/31/23       | 127               | 169        | nm         | nm   | nm     | Health Care Equipment            |



Transaction values over \$100 million; Presented in \$millions

Data Source: Capital IQ

# MedTech & Device M&A

(continued)

Medtech & Device M&A



## Initial Public Offerings



| Completed Initial Public Offerings During 3Q 2023 |               |          |           |                        |                     |                  |                    |                                  |
|---------------------------------------------------|---------------|----------|-----------|------------------------|---------------------|------------------|--------------------|----------------------------------|
| Issuer                                            | Ticker        | IPO Date | IPO Price | Gross Proceeds (\$mil) | 6/30/22 Stock Price | Return Since IPO | 9/29/23 Market Cap | Industry                         |
| SCHOTT Pharma AG & Co. KGaA                       | XTRA:1SXP     | 9/27/23  | 28.40     | 210.4                  | 33.49               | 17.9%            | 5,043.9            | Life Sciences Tools and Services |
| RayzeBio, Inc.                                    | NasdaqGM:RYZB | 9/14/23  | 18.00     | 311.0                  | 22.20               | 23.3%            | 1,228.0            | Biotechnology                    |
| CurveBeam AI Limited                              | ASX:CVB       | 8/16/23  | 0.31      | 16.1                   | 0.27                | -13.5%           | 85.7               | Health Care Equipment            |
| NeurAxis, Inc.                                    | NYSEAM:NRXS   | 8/8/23   | 6.00      | 6.6                    | 3.80                | -36.7%           | 18.9               | Health Care Equipment            |
| iVision Tech S.p.A.                               | BIT:IVN       | 7/28/23  | 1.27      | 2.2                    | 1.62                | 28.1%            | 11.3               | Health Care Supplies             |
| EcoNaviSta, Inc.                                  | TSE:5585      | 7/26/23  | 9.26      | 10.2                   | 19.36               | 109.0%           | 117.9              | Health Care Equipment            |

Data Source: Capital IQ

# Initial Public Offerings

(continued)

Medtech & Device IPOs



Source: Capital IQ; Mercer Capital Analysis



**Mercer Capital**

[www.mercercapital.com](http://www.mercercapital.com)

